Phase II Study of the Efficacy of the EGFR Inhibitor Mefatinib in Patients with Advanced EGFR-mutant NSCLC

被引：0
|
作者：
Wang, P. [1 ]
Li, Y. [2 ]
Lv, D. [3 ]
Ding, L. [1 ]
Hong, W. [4 ]
Han-Zhang, H. [5 ]
Lin, J. [5 ]
Zhou, J. [6 ]
Wang, K. [1 ]
机构：
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Resp Med, Hangzhou, Peoples R China
[2] Wenzhou Med Univ, Affiliated Hosp 1, Dept Pulm & Crit Care Med, Wenzhou, Peoples R China
[3] Wenzhou Med Univ, Taizhou Hosp, Dept Resp Med, Taizhou, Peoples R China
[4] Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China
[5] Burning Rock Biotechnol Co Ltd, Guangzhou, Peoples R China
[6] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Resp Dis,Thorac Dis Ctr, Hangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
EGFR Inhibitor; Mefatinib; advanced NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.28
引用
收藏
页码：S598 / S599
页数：2
相关论文
共 50 条
  • [21] Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients
    Ruglioni, Martina
    Petrini, Iacopo
    Crucitta, Stefania
    Sbrana, Andrea
    Luculli, Giovanna Irene
    Gol, Leila Sadeghi
    Forte, Carola
    Chella, Antonio
    Rolfo, Christian
    Danesi, Romano
    Del Re, Marzia
    TRANSLATIONAL ONCOLOGY, 2025, 52
  • [22] Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients
    Yan, Dan
    BIOMEDICINES, 2023, 11 (11)
  • [23] How I treat patients with EGFR-mutant NSCLC
    Aggarwal, Charu
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (11): : 387 - 387
  • [24] A new standard for EGFR-mutant NSCLC?
    David Killock
    Nature Reviews Clinical Oncology, 2019, 16 : 593 - 593
  • [25] A multi-center phase II study of toripalimab with chemotherapy in patients with EGFR mutant advanced NSCLC patients resistant to EGFR TKIs: Efficacy and biomarker analysis.
    Ren, Shengxiang
    Zhang, Jie
    Zhao, Yanqiu
    Mu, Xiaoqian
    Zhou, Jianying
    Bao, Zhang
    Fan, Yun
    Xu, Yanjun
    Shu, Yongqian
    Guo, Renhua
    Liu, Xiaoqing
    Wang, Hong
    Zhang, Helong
    Deng, Lin
    Ma, Ningqiang
    He, Jianxing
    Zhang, Yalei
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Plasma microRNA signatures to predict EGFR-TKI resistance in EGFR-mutant advanced NSCLC patients.
    Wang, Shuhang
    Wang, Jie
    Bai, Hua
    An, Tongtong
    Zhao, Jun
    Wang, Zhijie
    Duan, Jianchun
    Zhuo, Minglei
    Wang, Yuyan
    Wu, Meina
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
    Lim, S. M.
    Cho, B. C.
    Han, J-Y.
    Kim, S-W.
    Lee, K. H.
    Nagasaka, M.
    Baisamut, T. R.
    Jo, A.
    Seah, E.
    Kim, C.
    Ou, S-H. I.
    ANNALS OF ONCOLOGY, 2023, 34 : S1704 - S1705
  • [28] Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
    Gillis, R.
    Peled, N.
    Goldshtien, I.
    Rotem, O.
    Rozenblum, A. B.
    Nechushtan, H.
    Chen, L.
    Dudnik, E.
    Zer, A.
    Yust-Katz, S.
    Shelef, I.
    Roisman, L. C.
    Inbar, E.
    ANNALS OF ONCOLOGY, 2019, 30
  • [29] Cytoplasmic ERβ expression to predict efficacy and survival of EGFR-TKI in EGFR-mutant NSCLC
    Wang, Zhijie
    Wang, Jie
    Wang, Xiaodong
    Shen, Zhirong
    Ding, Xiaosheng
    Bai, Hua
    Duan, Jianchun
    An, Tongtong
    Wang, Yuyan
    Zhuo, Minglei
    Wang, Shuhang
    Wu, Meina
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
    Wu, Shang-Gin
    Ho, Chao-Chi
    Yang, James Chih-Hsin
    Yu, Shu-Han
    Lin, Yen-Feng
    Lin, Shu-Chin
    Liao, Bin-Chi
    Yang, Ching-Yao
    Lin, Yen-Ting
    Yu, Chong-Jen
    Chuang, Ya-Ting
    Liao, Wei-Yu
    Yap, Kah Yi
    Kou, Weng Si
    Shih, Jin-Yuan
    CLINICAL AND TRANSLATIONAL MEDICINE, 2025, 15 (01):
12345